PTU (propylthiouracil) is considered the safest antithyroid medication during the first trimester of pregnancy and is recommended by both the American Thyroid Association and the Endocrine Society as the preferred treatment for hyperthyroidism in early pregnancy. It is not without risks, but for most women with overactive thyroid conditions like Graves’ disease, the benefits of treatment outweigh the dangers of leaving hyperthyroidism uncontrolled.
Why PTU Is Preferred in the First Trimester
The main alternative to PTU is methimazole, which is linked to a specific pattern of birth defects when taken during the first trimester. These defects occur during organogenesis, the critical window when a baby’s organs are forming. A large meta-analysis published in PLOS One found that women treated with methimazole had a significantly higher risk of congenital anomalies compared to those treated with PTU.
PTU also crosses the placenta less readily than methimazole. Studies measuring drug levels in fetal blood after a single maternal dose show that methimazole passes through the placenta at notably higher rates, exposing the developing baby to more of the drug. This difference in placental transfer is one reason PTU is considered the safer choice during early fetal development.
If you’re already taking methimazole and become pregnant, current guidelines recommend switching to PTU as soon as pregnancy is confirmed in the first trimester. Your thyroid levels should be rechecked about two weeks after the switch and then every two to four weeks to make sure levels stay stable during the transition.
The Switch Back After Week 16
PTU is not the ideal long-term choice throughout pregnancy. After about gestational week 16, guidelines recommend considering a switch back to methimazole. The reason: PTU carries a rare but serious risk of liver damage that methimazole does not share to the same degree. The FDA has placed a boxed warning on PTU for severe liver injury and acute liver failure, including fatal cases. Some of these cases have occurred in pregnant women.
Because the risk of methimazole-related birth defects is concentrated in the first trimester, the strategy is straightforward. Use PTU during the weeks when organ formation is most vulnerable, then transition to methimazole once that window has passed to minimize your cumulative exposure to PTU’s liver risks. Your provider will monitor thyroid function closely during the switch to prevent any gap in treatment.
How PTU Works During Pregnancy
PTU blocks the production of new thyroid hormones in two ways. Inside the thyroid gland, it prevents iodine from being incorporated into the building blocks that become T4 and T3, your body’s two main thyroid hormones. It also blocks the conversion of T4 into T3 in the rest of your body. T3 is the more active form of thyroid hormone, so this second effect helps bring hormone levels down faster.
Typical starting doses are around 100 mg three times daily, with the goal of gradually reducing to a maintenance dose of 100 to 200 mg per day. During pregnancy, the general approach is to use the lowest effective dose. Keeping maternal PTU doses at or below 300 mg daily is associated with satisfactory thyroid control without causing clinically significant thyroid problems in the baby.
Risks of Untreated Hyperthyroidism
The risks of PTU need to be weighed against what happens when hyperthyroidism goes untreated during pregnancy. A retrospective study comparing pregnancy outcomes found that women with untreated thyrotoxicosis had a miscarriage rate of 2.5%, five times higher than the 0.5% rate in women without thyroid disease. Preeclampsia rates told a similar story: 9 to 10% in untreated women compared to about 4.4% in controls.
Women who received antithyroid drug treatment fared better. Their preeclampsia rate dropped to around 8.1%, compared to 10.1% in the untreated group. These numbers make clear that while no medication is completely risk-free, uncontrolled hyperthyroidism poses its own serious threats to both mother and baby, including premature delivery, low birth weight, and thyroid storm.
Effects on the Baby’s Thyroid
Because PTU crosses the placenta to some degree, it can suppress the baby’s thyroid function as well as the mother’s. At maternal doses of 300 mg or less per day, neonatal thyroid function generally remains normal. Higher doses increase the chance of the baby developing a temporary goiter (enlarged thyroid gland) or being born with mildly underactive thyroid levels. This is one reason providers aim for the minimum dose that keeps maternal thyroid hormones in a safe range, checking free T4 levels roughly every month to fine-tune the dose.
PTU and Breastfeeding
PTU passes into breast milk in very small amounts. After a 400 mg dose, peak milk levels averaged just 0.7 mg per liter. Researchers estimated that even at a full therapeutic dose of 200 mg three times daily, a nursing infant would receive no more than about 0.025% of the mother’s dose. This extremely low transfer rate means PTU is generally compatible with breastfeeding, and thyroid function in breastfed infants of mothers taking PTU has not shown clinically meaningful changes in studies.